Most material SEC filings — August 17, 2026

On August 16, 2026, Dermata Therapeutics (market cap ~$3.1M) sold approximately $3.36M aggregate subscription amount of common stock, pre-funded warrants ($0.001 exercise price, exercisable immediately), Series E common warrants (5-year term, $1.46–$1.47 exercise price), and Series F common warrants (24-month term, $1.46–$1.47 exercise price) to multiple accredited investors under Regulation D Rule 506. Purchasers receive equal treatment, anti-dilution protections, registration rights, and potential liquidated damages for registration delays. The transaction requires stockholder approval for warrant issuance.

Axe Compute and Duos Technologies announced agreements for 55 MW of AI data center capacity across multiple U.S. locations, representing over $500 million in expected aggregate payments. Axe Compute will also acquire 49% equity stakes in project entities via nonbinding term sheets, expanding beyond its Georgia 10 MW deployment. Deployment targeted late 2026 through early 2027, subject to construction and approvals.

Nexalin Technology, Inc. (market cap ~$14.7M) received notice on 2026-08-14 of delisting or failure to satisfy continued listing rules and standards, with transfer of listing. No specific cure details, remediation timeline, or financial metrics disclosed in this 8-K filing.

Adial Pharmaceuticals completed acquisition of Azora Therapeutics (adding AT177, a colon-targeted AhR agonist for ulcerative colitis) and closed initial $32 million tranche of up to $64 million private placement from biotech investors (including $5.5 million note conversion). Company pivot: from addiction-focused to autoimmune/inflammatory disease focus. Cash position improved to $28.7M as of June 30, 2026 from $4.6M on March 31, 2026; runway extended to second half 2027. Q2 2026 net loss was $52.0M ($11.25/share on 4.6M weighted-avg shares), primarily driven by $46.2M non-cash in-process R&D charge.

On May 18, 2026, Quince Therapeutics acquired Orphai Therapeutics via merger, issuing 67,101 shares of Series C Preferred Stock (convertible to 3.5M common shares) to Orphai stockholders. Concurrently, Quince closed a $115M PIPE on May 21, 2026, selling 144,201 shares of Series C Preferred Stock at $797.50/share and warrants to purchase 72,100 shares at $996.90/share to new and returning investors, generating up to $187M total (including warrant exercise proceeds). Post-conversion, common shares outstanding increase from 1.0M to 12.0M.

On August 17, 2026, Valion Bio received $1.5M from 3i, LP (Initial Closing) for 1,500 Series B Preferred Shares, contingent on CEO Michael Handley's removal. A second $1.5M closing is optional if parties execute a definitive side letter by August 24, 2026. Separately, Valion executed a 10-year royalty agreement with multiple payees (3i, LP and others) obligating Velocity Bioworks subsidiary to pay 5% of gross business revenue quarterly, with Valion guaranteeing payments. The royalty agreement has no dollar cap and runs through 2036.

Fulcrum Therapeutics (NASDAQ: $296.1M market cap) agreed to acquire private biotech Slate Medicines in an all-stock merger dated August 16, 2026. Slate shareholders receive Parent Common Stock at an Exchange Ratio based on a $350M pre-money Company Valuation plus concurrent $245M+ investment. Parent Valuation set at $31.3M (assuming $20.3M Net Cash post-dividend). Merger structure: two-step (First Merger Sub merges into Company, then surviving company merges into Second Merger Sub). Company stockholders and Parent stockholders must each approve. Pre-Closing Cash Dividend to Parent shareholders; concurrent investors funding $245M+.

Abundia Global Impact Group, Inc. (market cap ~$17.9M) obtained a $10 million secured credit facility from Bower Family Holdings, LLC (its largest shareholder) dated August 15, 2026. The facility has a 2-year term, 10% annual interest, with an initial $6.5 million drawdown and optional tranches of $0.5M+ thereafter. Proceeds will repay $4.193M of a convertible note due to Abundia Financial and provide working capital. The debt is secured by company and subsidiary assets via UCC filings and a mortgage.

Check-Cap Ltd (Israeli medical diagnostics company, $7.5M assets) is acquiring MBody AI, an embodied AI robotics-software company, via merger expected Q3 2026. Check-Cap shareholders will own ~10% post-merger; MBody AI shareholders ~90%. Concurrently, Check-Cap is raising $12.5M (1.43M shares at $8.72/share) for merger expenses, robot deployments, and platform development. The company also acquired Ghost Kitchen franchise rights in New Jersey for 1.17M shares on Sept 4, 2025. Pending Nasdaq listing approval; going-concern doubt disclosed.

Prairie Operating Co. executed a Third Amendment to its Amended and Restated Credit Agreement with Citibank (Administrative Agent), KeyBank, MUFG Bank, and UMB Bank, effective June 30, 2026. The amendment relaxes the current ratio covenant (0.50–1.0 for Q2 2026, stepping to 1.0 by Q1 2027), adds a new minimum hydrocarbon production covenant (660–712 BOE/day from August 2026 onward per Schedule 9.23), and imposes bi-weekly 13-week cash flow and accounts-payable reporting. Specific dollar amounts of the credit facility are not disclosed in this amendment excerpt. The borrower released all prior claims against lenders in exchange for the amendment.

L3Harris CEO and Chairman Christopher Kubasik separated from the company effective August 16, 2026, following Board discovery of conduct inconsistent with Company Code of Conduct (unrelated to financial reporting, controls, or operations). Sam Mehta, President of SMS and CSD segments (>80% of revenue), appointed as new President and CEO; Lewis Hay III named Independent Chairman. Kubasik retains 384,825 vested stock options (exercise prices $181.91–$233.51 per share, exercisable for 90 days) and accrued benefits but forfeits all other equity awards and 2026 bonus. 2026 financial guidance reaffirmed.

NRX Pharmaceuticals completed FDA review of its ANDA for preservative-free ketamine (NRX-100) with no major drug deficiencies; sole remaining item is manufacturer's attestation on vial connector, already submitted. Company raised $22.3M gross in public offering, now has $26.7M cash (vs. $7.8M at year-end 2025), and is manufacturing 5M doses for anticipated 2026 commercialization. Additionally, DARPA selected NRX as prime contractor for $11.5M+ SPARC-TMS trial of NRX-101 for depression, potentially expanding addressable market from ~1M to 15M patients.

NexGel reported Q2 2026 revenue of $3.69 million and net loss of $2.87 million (ending June 30, 2026). The company completed its Celularity acquisition in mid-April 2026, forming the BioNX Surgical division, but integration and revenue ramp proceeded slower than anticipated due to ongoing supply chain constraints, resulting in approximately $795,000 backlog. Non-recurring charges included $756,554 in intangible asset amortization, $273,710 in transaction costs, and $144,495 for SilverSeal inventory recall to support hospital market launch. Failed shareholder vote on authorized shares and reverse split (due to broker non-votes) will be re-solicited as standalone proposals by late September 2026.

HomeTrust Bancshares agreed to acquire Blue Ridge Bankshares (Company) in an all-stock merger dated August 16, 2026. Company shareholders will receive 0.086 HomeTrust shares per Company share held, with no cash consideration except for fractional shares. The merger involves two steps: Merger Sub merges into Company, then Company merges into HomeTrust, followed by a subsidiary bank merger. All parties have obtained fairness opinions and executed voting agreements.

HomeTrust Bancshares agreed to acquire Blue Ridge Bankshares in an all-stock merger whereby Blue Ridge shareholders receive 0.086 HomeTrust shares per share held. The transaction is structured as a two-step merger followed by a bank subsidiary merger. As of August 16, 2026, Blue Ridge had 89.7 million shares outstanding; the exchange ratio values the deal at approximately $17M based on HomeTrust's ~$196.9M market cap. Regulatory approvals and shareholder votes are required; closing expected within months.

As of August 16, 2026, Bitmine holds 5,815,164 ETH valued at ~$11.0B (at $1,893/ETH), representing 4.8% of the 120.7M total ETH supply, achieving 96% progress toward its 5% acquisition target. The company repurchased 1.7M common shares in the past week and 20.8M cumulatively since July 2026 under a $4B authorization. Staked ETH totals 5,067,309 tokens ($9.6B), with projected annualized staking revenues of $250M–$287M.

Vulcan Infrastructure & Power announced a $39.4 million private investment in public equity (PIPE) transaction led by Machine Investment Group, Atlas Holdings, and Conversant Capital. Proceeds will redeem approximately $33.1 million in aggregate principal of 8.50% Senior Notes due October 2026, reducing total debt from $36.9 million to $13.7 million (or $3.7 million post-convertible note conversion). The transaction includes a $10 million secured convertible note to Machine at $2.1375/share conversion price. Post-closing, Machine owns ~22.4%, Conversant ~8.3%, Atlas diluted to ~17.0% ownership. The company will issue ~17.1 million PIPE shares at $1.71/share (deal price; stock at $1.84 post-announcement).

FingerMotion, Inc. (public market value ~$72.8M) entered a Securities Purchase Agreement dated August 16, 2026, with Alto Opportunity Master Fund, SPC Segregated Master Portfolio B to issue $4.3M in principal amount of Senior Secured Convertible Notes due August 16, 2027, plus warrants for 4,092,993 shares. Notes are convertible at $0.35/share (fixed), with a 0% interest rate in normal circumstances and 12% if an Event of Default occurs. Lead Investor Alto Opportunity receives pro-rata participation rights in future financings (30% cap), anti-dilution protection, and voting rights. Proceeds are released in three tranches ($1.3M immediately, $2M and $1M subject to note value conditions). Company must obtain stockholder approval to issue shares exceeding 12.256M (19.99% of outstanding shares). Alto Opportunity appointed as Collateral Agent with first-priority security interest in substantially all company assets.

Chief Executive Officer Seto Wai Yue (TDIC) bought 972K shares (~$3.6M) on the open market (48% of holdings). Open-market insider purchase — historically a bullish signal.

Director Troim Tor Olav (BORR) bought 500K shares (~$2.2M) on the open market (1.7% of holdings). Open-market insider purchase — historically a bullish signal.

InspireMD reported Q2 2026 revenue of $1.8M (flat vs. Q2 2025), but U.S. operations posted a negative $351K due to a voluntary May 2026 recall of the CGuard Prime 135 cm delivery system, which generated $734K in customer credits and $612K inventory impairment. The company hired Kathleen Kennedy as SVP Global Sales & Marketing, commenced CGUARDIANS III trials, and initiated post-quarter cost-reduction actions targeting $9M annual savings. Cash declined 44% to $30.4M (from $54.2M year-end 2025); H1 2026 net loss was $28M. FDA decisions on CGuard Prime 80 cm (TCAR) and original CGuard (CAS) expected later in 2026.

Q2 2026: subscription revenue grew 164% YoY to $764K (now 62% of total revenue vs. 27% prior year); gross profit increased 53% YoY to $610K (49% margin vs. 37%); net loss narrowed to $1.7M from $2.2M. Company regained Nasdaq $1.00 minimum bid price compliance after 10 consecutive trading days at or above $1.00 (July 31–Aug 13, 2026). Cash position: $3.8M as of June 30, 2026.

UNIFI agreed to sell approximately 120 acres of land and 500,000 sq ft of warehouse space across two locations in Yadkin County, North Carolina for ~$60 million gross proceeds (before fees/expenses). The sale is expected to close in Q2 fiscal year, with proceeds allocated to debt reduction and balance sheet optimization. Management states the transaction will have minimal operational impact, with no changes to production capacity or customer service.

Executive Officer & Co-CEO Coppetti Caspar Felix (ONON) bought 65K shares (~$2.0M) on the open market (2.6% of holdings). Open-market insider purchase — historically a bullish signal.

Executive Officer Bernhard Olivier (ONON) bought 65K shares (~$2.0M) on the open market (1.2% of holdings). Open-market insider purchase — historically a bullish signal.

Gray Media (NYSE: GTN) announced on August 17, 2026, an offering of up to $750 million in senior secured first lien notes due 2034. Net proceeds will be used to redeem a portion of its 10.500% senior secured first lien notes due 2029, repay borrowings under its revolving credit facility, and cover offering fees and expenses. The notes will be offered to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S.

For Q2 2026, Prairie Operating Co. reported total revenues of $98.9M (up 45% YoY), net income attributable to common stockholders of $193.8M ($1.75 basic EPS, $0.23 diluted EPS), and Adjusted EBITDA of $34.0M. YTD 2026 revenue totaled $182.3M (up 125% YoY) with Adjusted EBITDA of $71.1M (up 65% YoY). The company drilled 27 wells YTD, executed a partial Series F preferred stock refinancing in April reducing warrant dilution, and raised 2026 guidance: production 23,000–25,000 Boe/d, capex $185M–$195M, Adjusted EBITDA $180M–$190M. As of June 30, the company had a working capital deficit of $125.5M, $39.0M available under its $475M credit facility, and borrowed $436M on the credit facility.

AmpliTech reduced the Titan Crest Asset Purchase Agreement price by $1M (from $8M to $7M) while retaining all rights and claims. The company reports $17M in current 5G ORAN backlog, $6M in follow-on orders announced in July, and >2,000 radios shipped to a Tier-1 MNO. Management expects 2026 revenue to exceed 2025 levels, with margin improvement and positive EBITDA targeted for 2027, supported by a pending RFP from a Tier-1 telecom infrastructure provider (potential tens of millions if awarded).

Brandywine Realty Trust's operating partnership commenced concurrent cash tender offers for up to $100M aggregate principal amount of outstanding debt: $50M of 7.550% notes due March 2028 (offering $1,047.50 per $1,000 principal) and $50M of 8.875% notes due April 2029 (offering $1,068.75 per $1,000 principal). Tender period expires August 21, 2026; settlement anticipated August 25, 2026. The 2028 Notes' coupon has increased 75 bps to 8.30% due to credit rating downgrades since issuance. Funding will come from cash on hand or borrowings under the company's $600M credit facility.

Serve Robotics announced a partnership with Grubhub (Wonder subsidiary) bringing robot delivery to 100+ Chicago merchants and ~200 Los Angeles merchants, plus Wonder's Alexandria location. Simultaneously, Serve launched in Washington DC and San Jose (7th and 8th major markets, population 8M combined), opened its first micro-depot in Miami, and began rolling out Moxi 2.0 hospital robots with 15x faster processing to health systems including Endeavor Health and Providence Saint John's. New products include Beacon (countertop restaurant device) and Characters (interactive advertising featuring Chomp, a talking hamburger robot).

INVO Fertility reported Q2 2026 revenue of $2.175M (up 17% YoY from $1.864M), driven by full-quarter contribution from February 2026 Family Beginnings acquisition and organic growth. Clinic-Level Adjusted EBITDA was $333K in Q2 2026 vs. $164K in Q1 2026. In June 2026, INVO acquired remaining ownership interests in Birmingham clinic, converting from joint venture to wholly-owned subsidiary. Net income was $0.9M (vs. $3.6M loss YoY), but included $2.5M non-cash gain on Birmingham remeasurement; Adjusted EBITDA remained negative at $(1.0M). Cash position improved to $3.7M vs. $2.1M at year-end 2025.

NOAA published a Notice of Intent in the Federal Register on August 17, 2026, to prepare an Environmental Impact Statement for TMC USA's exploration license application covering ~122,000 km² in the Clarion Clipperton Zone, estimated to contain 1.02 billion tonnes of polymetallic nodules. This follows NOAA's May 26, 2026 certification of the USA-B application and represents a procedural milestone; NOAA will next publish a draft EIS and draft Terms, Conditions & Restrictions for public comment, then finalize and decide whether to issue the license. TMC USA also has a consolidated USA-A application (submitted January 22, 2026, deemed fully compliant April 28, 2026) progressing in parallel.

AMASS Brands (Nasdaq: AMSS) reported Q2 2026 net revenue of $5.6M (+2% YoY), with Core Brands growing 12% to represent 67% of brand revenue (vs. 62% prior year). Non-Alcoholic & Functional segment revenue surged 132% to $0.4M. The company completed its May 20 Nasdaq direct listing and introduced initial guidance: FY2026 minimum $18.5M revenue (+4% growth), FY2027 minimum $22.2M (+20% growth). Key wins include Good Twin becoming #1 organic non-alcoholic wine by Nielsen share, Pizzolato MUSE #1 organic sparkling wine, national Whole Foods expansion, and announced acquisition of majority stake in HpO sparkling protein water. However, adjusted EBITDA was negative $1.7M; cash declined to $1.6M; and the company flagged going-concern doubts and need for additional capital.

EyePoint announced topline results from LUGANO, a pivotal Phase 3 trial of DURAVYU (vorolanib intravitreal insert) in wet AMD with ~427 patients enrolled. The primary endpoint (non-inferiority in BCVA change vs. aflibercept at Weeks 52/56) was not achieved in the full dataset; however, when excluding 9 patients (4% of 211 DURAVYU arm) who experienced ≥15 letter vision loss from non-wet AMD causes (geographic atrophy, glaucoma, retinal detachment), DURAVYU achieved non-inferiority (nominal p=0.0096). Key secondary endpoints were met: 42% reduction in treatment burden vs. aflibercept (p=0.0001), 76% supplement-free at Week 32, 54% at Week 56, and favorable safety with repeat dosing. The second pivotal trial (LUCIA) is expected in Q4 2026, with potential NDA submission in H1 2027.